全文获取类型
| 收费全文 | 215982篇 |
| 免费 | 15826篇 |
| 国内免费 | 979篇 |
专业分类
| 耳鼻咽喉 | 2344篇 |
| 儿科学 | 5798篇 |
| 妇产科学 | 4425篇 |
| 基础医学 | 28009篇 |
| 口腔科学 | 4589篇 |
| 临床医学 | 20617篇 |
| 内科学 | 45893篇 |
| 皮肤病学 | 2824篇 |
| 神经病学 | 20857篇 |
| 特种医学 | 7084篇 |
| 外国民族医学 | 13篇 |
| 外科学 | 34097篇 |
| 综合类 | 3566篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 292篇 |
| 预防医学 | 19637篇 |
| 眼科学 | 4485篇 |
| 药学 | 14729篇 |
| 1篇 | |
| 中国医学 | 377篇 |
| 肿瘤学 | 13148篇 |
出版年
| 2023年 | 871篇 |
| 2022年 | 1442篇 |
| 2021年 | 3519篇 |
| 2020年 | 2140篇 |
| 2019年 | 3466篇 |
| 2018年 | 4075篇 |
| 2017年 | 3269篇 |
| 2016年 | 3489篇 |
| 2015年 | 4142篇 |
| 2014年 | 6187篇 |
| 2013年 | 9019篇 |
| 2012年 | 13365篇 |
| 2011年 | 14586篇 |
| 2010年 | 8216篇 |
| 2009年 | 7431篇 |
| 2008年 | 13857篇 |
| 2007年 | 14690篇 |
| 2006年 | 14223篇 |
| 2005年 | 14677篇 |
| 2004年 | 14080篇 |
| 2003年 | 13136篇 |
| 2002年 | 12672篇 |
| 2001年 | 2123篇 |
| 2000年 | 1673篇 |
| 1999年 | 2220篇 |
| 1998年 | 2907篇 |
| 1997年 | 2511篇 |
| 1996年 | 2274篇 |
| 1995年 | 2024篇 |
| 1994年 | 1808篇 |
| 1993年 | 1707篇 |
| 1992年 | 1368篇 |
| 1991年 | 1286篇 |
| 1990年 | 1183篇 |
| 1989年 | 1084篇 |
| 1988年 | 1132篇 |
| 1987年 | 1129篇 |
| 1986年 | 1087篇 |
| 1985年 | 1164篇 |
| 1984年 | 1565篇 |
| 1983年 | 1534篇 |
| 1982年 | 1858篇 |
| 1981年 | 1682篇 |
| 1980年 | 1586篇 |
| 1979年 | 887篇 |
| 1978年 | 1017篇 |
| 1977年 | 981篇 |
| 1976年 | 870篇 |
| 1975年 | 724篇 |
| 1974年 | 697篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
1.
Katja T. Turunen Vasiliki Pletsa Panagiotis Georgiadis John K. Triantafillidis Dimitrios Karamanolis 《Nutrition and cancer》2016,68(4):560-567
The aim of the study was to determine the effect of β-glucan on the cytotoxicity and genotoxicity of polypectomized patient's fecal water (FW). Polypectomized volunteers (n = 69) were randomly assigned to consume bread with or without β-glucan, for 3 months. FW was collected at the beginning (t = 0), the 30th and 90th day and 2 wk after the intervention. Cytotoxicity and genotoxicity were estimated on Caco-2 cells, using trypan blue exclusion test and comet assay, respectively. Gastrointestinal symptoms were recorded and subjects kept a 3-day food diary at baseline and after completion. Trypan blue exclusion test revealed cell survival of approximately 87% after incubation with FW. The FW samples showed 49% genotoxicity at the baseline. Genotoxicity in the intervention group decreased during the trial reaching statistical significance on the 90th day compared to control. An increase was noticed 2 wk after the trial, but it still remained significantly lower compared to control. Group-specific analysis for β-glucan also revealed significant decrease in the genotoxicity on the 90th day compared to baseline. β-glucan ingestion in polypectomized patients significantly decreased the genotoxicity of their FW. Our findings suggest that β-glucan consumption could possibly provide protection against colon cancer development. 相似文献
2.
3.
4.
5.
6.
7.
8.
Clint R. Bellenger John B. Arnold Jonathan D. Buckley Dominic Thewlis Joel T. Fuller 《Journal of Science and Medicine in Sport》2019,22(3):294-299
Objectives
To investigate whether functional overreaching affects locomotor system behaviour when running at fixed relative intensities and if any effects were associated with changes in running performance.Design
Prospective intervention study.Methods
Ten trained male runners completed three training blocks in a fixed order. Training consisted of one week of light training (baseline), two weeks of heavy training designed to induce functional overreaching, and ten days of light taper training designed to allow athletes to recover from, and adapt to, the heavy training. Locomotor behaviour, 5-km time trial performance, and subjective reports of training status (Daily Analysis of Life Demands for Athletes (DALDA) questionnaire) were assessed at the completion of each training block. Locomotor behaviour was assessed using detrended fluctuation analysis of stride intervals during running at speeds corresponding to 65% and 85% of maximum heart rate (HRmax) at baseline.Results
Time trial performance (effect size ±95% confidence interval (ES): 0.16 ± 0.06; p < 0.001), locomotor behaviour at 65% HRmax (ES: ?1.12 ± 0.95; p = 0.026), and DALDA (ES: 2.55 ± 0.80; p < 0.001) were all detrimentally affected by the heavy training. Time trial performance improved relative to baseline after the taper (ES: ?0.16 ± 0.10; p = 0.003) but locomotor behaviour at 65% HRmax (ES: ?1.18 ± 1.17; p = 0.048) and DALDA (ES: 0.92 ± 0.90; p = 0.045) remained impaired.Conclusions
Locomotor behaviour during running at 65% HRmax was impaired by functional overreaching and remained impaired after a 10-day taper, despite improved running performance. Locomotor changes may increase injury risk and should be considered within athlete monitoring programs independently of performance changes. 相似文献9.
Katherine M. Duszynski Nicole L. Pratt John W. Lynch Jesia G. Berry Michael S. Gold 《Vaccine》2019,37(2):280-288
Objective
To determine whether differences in combination DTaP vaccine types at 2, 4 and 6?months of age were associated with mortality (all-cause or non-specific), within 30?days of vaccination.Design
Observational nationwide cohort study.Setting
Linked population data from the Australian Childhood Immunisation Register and National Death Index.Participants
Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6?months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3?million children in the 2, 4 and 6?month vaccine cohorts, respectively.Main outcome measures
Infants were evaluated for the primary outcome of all-cause mortality within 30?days. A secondary outcome was non-specific mortality (unknown cause of death) within 30?days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 ‘Sudden infant death syndrome’, R96 ‘Other sudden death, cause unknown’, R98 ‘Unattended death’, R99 ‘Other ill-defined and unspecified cause of mortality’ or where no cause of death was recorded.Results
The rate of 30?day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6?month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort.Conclusion
Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality. 相似文献10.